FDA, supplement regulation and the 2024 outlook

FDA’s director of the Office of Dietary Supplement Programs (ODSP), Dr. Cara Welch, will present an overview of the agency’s FY23 activities related to dietary supplements and FY24 plans, as well as an update on the pending Human Foods Program reorganization. This will be followed by a Q&A with our audience and a panel discussion with other industry regulatory experts. Important topics include good manufacturing practice (GMP) inspections, new dietary ingredient (NDI) responses, enforcement actions, FDA/ODSP priorities, NDI guidance, ingredients of particular concern to the agency and more.